"Hijack" protein function to cure the incurable, says Kymera CMO

Located at the heart of the Cambridge biotech cluster in Massachusetts, USA, Kymera Therapeutics is exploring the notion that targeted protein degradation could provide a way to treat previously untreatable conditions.

To do this, the firm is using its proprietary Pegasus technology, what it calls a “game-changing integrated degradation platform,” to attack inflammation-related diseases.

As chief medical officer Jared Gollob says, the approach will allow Kymera to “hijack, or co-opt, the cells' normal mechanism for maintaining protein homeostasis.”